Carnegie Investment Counsel Sells 8,634 Shares of CVS Health Corporation $CVS

Carnegie Investment Counsel reduced its stake in shares of CVS Health Corporation (NYSE:CVS) by 17.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,061 shares of the pharmacy operator’s stock after selling 8,634 shares during the quarter. Carnegie Investment Counsel’s holdings in CVS Health were worth $2,877,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Caitong International Asset Management Co. Ltd grew its holdings in CVS Health by 407.2% during the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after purchasing an additional 281 shares during the period. Swiss RE Ltd. acquired a new stake in CVS Health in the fourth quarter worth $26,000. Sankala Group LLC bought a new position in shares of CVS Health during the fourth quarter worth $28,000. Global Trust Asset Management LLC grew its holdings in shares of CVS Health by 344.8% in the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock valued at $28,000 after buying an additional 300 shares during the period. Finally, Mcguire Capital Advisors Inc. acquired a new position in shares of CVS Health in the 4th quarter valued at $28,000. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Price Performance

CVS stock opened at $104.15 on Monday. The stock has a 50-day moving average price of $96.91 and a two-hundred day moving average price of $84.21. The stock has a market cap of $132.88 billion, a PE ratio of 45.88, a price-to-earnings-growth ratio of 1.02 and a beta of 0.61. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. CVS Health Corporation has a 1 year low of $58.50 and a 1 year high of $106.15.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The company had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities analysts forecast that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd will be given a dividend of $0.665 per share. The ex-dividend date of this dividend is Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.6%. CVS Health’s dividend payout ratio is 117.18%.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health declared a quarterly dividend of $0.665 per share, reinforcing its shareholder-return policy and signaling management confidence in cash generation. CVS Health declares quarterly dividend
• Positive Sentiment: Coverage around CVS highlighted the company as a likely beneficiary of managed-care consolidation, with commentary that Aetna is handling medical costs and that CVS is well positioned as Walgreens weakens. Cramer’s Stop Trading: CVS Health
• Neutral Sentiment: A CVS executive, Ali Keshavarz, was appointed to the board of Choice Hotels; this is notable for the executive’s profile but does not appear to have a direct operational impact on CVS. Choice Hotels (CHH) Appoints CVS Data Chief To Board As Index Changes Hit
• Negative Sentiment: CVS and Omnicare agreed to a $440 million settlement with the U.S. Department of Justice to resolve improper billing allegations, which creates a large one-time legal cost and keeps regulatory pressure on the company. CVS, Omnicare ink $440M deal with DoJ to resolve improper billing case
• Negative Sentiment: CVS also settled a separate $36.5 million case tied to false Medicaid insulin claims, adding to the legal overhang and reinforcing concerns about compliance risks. CVS settles for $36.5M over false Medicaid insulin claims, Minnesota recovers $400K

Analyst Upgrades and Downgrades

Several analysts recently commented on CVS shares. Cantor Fitzgerald raised their price objective on CVS Health from $100.00 to $110.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 7th. Sanford C. Bernstein increased their price target on CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a report on Tuesday, May 12th. Argus raised their price target on CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a research report on Thursday, May 14th. DA Davidson lifted their price objective on CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Finally, Wells Fargo & Company increased their target price on CVS Health from $102.00 to $103.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Twenty-one research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $102.84.

Insider Activity at CVS Health

In related news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares in the company, valued at approximately $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Larry Robbins sold 1,983,538 shares of the firm’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the completion of the transaction, the director directly owned 6,213,261 shares of the company’s stock, valued at approximately $586,842,501.45. This trade represents a 24.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,441,551 shares of company stock valued at $323,703,977 over the last ninety days. Company insiders own 0.85% of the company’s stock.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.